Prevalence of Sarcopenia in Women with Breast Cancer
D. Morlino(Federico II University Hospital), Fabrizio Pasanisi(Federico II University Hospital), Pietro De Placido(University of Naples Federico II), Carmine De Angelis(Baylor College of Medicine), Grazia Arpino(University of Naples Federico II), Maurizio Marra(Federico II University Hospital), E. Speranza(Federico II University Hospital), Lidia Santarpia(Federico II University Hospital), Annarita Verrazzo(Scuola Superiore Meridionale), Olivia Di Vincenzo(Sapienza University of Rome), Mario Giuliano(Regione Campania), Simone Carrano(Federico II University Hospital), Sabino De Placido, Giuseppe Buono(Federico II University Hospital), M. Naccarato(Federico II University Hospital), Iolanda Cioffi
Cited by 31
Related Papers
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance
|Endocrine Reviews|2008|545
A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models
|Cancer Research|2013|485
Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials
|Journal of Clinical Oncology|2007|413
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype
|Cancer Treatment Reviews|2018|282